Sun Pharma tumbles after report of probe

– Shares of India’s Sun Pharmaceutical Industries sank more than 10 percent on Monday after a report of a regulatory probe against the country’s biggest drug manufacturer by market value.

Markets regulator Securities and Exchange Board of India (SEBI) is likely to reopen an insider trading case against Sun, a report by the PTI carried https://economictimes.indiatimes.com/markets/stocks/news/sebi-may-reopen-insider-trading-case-against-sun-pharma/articleshow/66887801.cms in Indian daily Economic Times said.

The SEBI will also probe alleged lapses by some of Sun’s promoters in raising funds overseas, the report added.

A whistleblower approached the SEBI with a document alleging various irregularities by the Mumbai-headquartered company, its promoter Dilip Shanghvi and others, the report said.

Sun Pharma, its managing director and nine other entities had settled an insider trading probe last year after paying a settlement amount but the SEBI had not disclosed any details of the case at the time, the report added.

Sun did not immediately respond to a request from Reuters for comment.

Its shares hit their lowest in six months and were on course for their worst one-day performance in 18 months, weighing on the NSE index.

More than 37 million shares changed hands by 0647 GMT, over five times Sun’s 30-day moving average trading volume.

The stock has already fallen over 16 percent since mid-November, when the drugmaker reported a surprise loss for the September quarter.

In the days following its financial results a brokerage raised concerns over corporate governance practices at the company, according to media reports. Sun responded last week, saying any issues only concerned historic events.

(Reporting by Tanvi Mehta in Bengaluru; Editing by Sai Sachin Ravikumar)

  • Related Posts

    • Pharma
    • July 24, 2025
    • 356 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 373 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra